Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › Informatics › OpGen, Merck to Co-Develop Antibiotic Resistance Dx, Informatics

OpGen, Merck to Co-Develop Antibiotic Resistance Dx, Informatics

Nov 14, 2016
|
staff reporter

NEW YORK (GenomeWeb) – OpGen and Merck announced today that they will collaborate to develop rapid diagnostics and informatics tools for antibiotic resistance.

Under the terms of the deal, Merck will give OpGen access to its library of 200,000 bacterial pathogens in order to support OpGen's development of rapid DNA tests and a genomic database of antibiotic-resistant pathogens.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14
Featured Webinar

Development of a Metagenomics-based Pathogen-Detection Assay for SARS-CoV-2 Research

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Featured Webinar

Diagnostic Challenges in Cancer Immunotherapy: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In Molecular Diagnostics

  1. FDA Letter Warns About False-Positive Results From Becton Dickinson SARS-CoV-2 Test

  2. FDA Grants EUA for UCSF, Broad Institute, BioSewoom Coronavirus Tests

  3. Thermo Fisher Scientific, First Genetics to Develop NGS-Based Diagnostics in Russia

  4. SARS-CoV-2 Pandemic May Promote Progress in Paper MDx

    Premium

  5. FDA Issues New Guidance for SARS-CoV-2 Pooled Sample Testing

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.